Compare Quest Diagnostics Inc (DGX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard Value Index Fund ETF — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Vanguard Value Index Fund ETF trades at $218.38. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | VTV | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | — |
52-Week High | $216.02 | $220.51 |
52-Week Low | $166.42 | $175.51 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
VTV trades at $219.36, up 0.07% with a bullish technical outlook supported by moving averages and near-term resistance at $220. The ETF benefits from investor rotation into value stocks amid AI sector volatility, offering diversification with low tech exposure and a recent dividend declaration. It has gained 16% year-to-date, reflecting strong momentum in large-cap value equities.
The outlook remains positive as value stocks attract flows away from stretched growth valuations, though Fed policy and inflation risks could pressure returns. VTV's low expense ratio and defensive tilt provide stability, but macroeconomic shifts pose headwinds for continued outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
